Arena Pharmaceuticals, Inc.

Novartis Ag

Irm LLC

Jeffrey M Smith

Brian Christopher Smith

Valentina Molteni

Jon Christopher Loren

Yi Fan

Brenton Todd Flatt

Jeffrey T Schultz

Charles A Gilson, Iii

Pamela Ann Albaugh

Fupeng Ma

Yongping Xie

Advait Suresh Nagle

Xiaodong Liu

Fang Liang

Alec Nathanson Flyer

Gregory B Chopiuk

Duncan Shaw

Catherine Fooks Solovay

Jan Jiricek

Kathryn Taylor Linkens

Shuyi Pearly Ng

Maxim Ratnikov

Kelly D Boss

Declan Hardy

Zhihong Huang

Isabelle K Lerario

Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I'), or pharmaceutical composition described herein. 

1,2,4-oxadiazole derivatives as liver X receptor agonists

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.  

Compounds and compositions as TRK inhibitors

The present invention relates to novel compounds of Formula (I): which act as 5HTreceptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.

[object Object]

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.

5HT2C receptor modulators

The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.

Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases

5HT2c receptor modulators

Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases

The present invention relates to novel compounds of Formula (I):which act as 5HTreceptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.

Growing community of inventors

San Diego, CA, United States of America

Jeffrey M Smith